Israels Galmed to Acquire Colospan in Bid to Build $6B GI Medtech Platform
Israel's Galmed Pharmaceuticals is acquiring Colospan Ltd. to build a $6B GI medtech platform, leveraging Colospan's CE-marked bypass device.
Galmed Pharmaceuticals
Galmed Partners with Tel Aviv University to Test Brain Cancer Therapy Potential
Galmed Pharmaceuticals is partnering with Tel Aviv University to explore its drug Aramchol as a potential treatment for metastatic brain cancer.
Israeli Firm Galmed Reports Brain-Penetrating Drug Breakthrough
Galmed Pharmaceuticals has developed a brain-penetrating Aramchol formulation using nanotech, showing promise for Parkinson's and dementia treatments.
Israel’s Galmed Wins South Korea Patent for New Liver Disease Combination Therapy
Galmed Pharmaceuticals secures South Korea patent for innovative liver disease combination therapy, extending global protection.
Navigation